Table 1.
Anti-proliferative and cytotoxic activities of NSC765690 and NSC765599 against panels of NCI60 human cancer cell lines.
| Cancer Type | Panel/Cell Line | GI50 (μM) | TGI (μM) | LC50 (μM) | |||
|---|---|---|---|---|---|---|---|
| NSC765690 | NSC765599 | NSC765690 | NSC765599 | NSC765690 | NSC765599 | ||
| Leukemia | CCRF-CEM | 0.53 | 0.703 | 9.73 | 5.6 | >100 | >100 |
| HL-60(TB) | 0.51 | 0.586 | 2.09 | 2.68 | >100 | >100 | |
| K-562 | 0.37 | 0.628 | 10.2 | 19.1 | >100 | >100 | |
| MOLT-4 | 0.46 | 0.928 | 2.05 | 3.39 | >100 | >100 | |
| RPMI-8226 | 0.23 | 0.248 | 0.74 | 0.951 | >100 | >100 | |
| SR | 1.91 | 1.95 | >100 | 8.27 | >100 | >100 | |
| NSCLC | A549/ATCC | 0.44 | 1.05 | 7.96 | 10.6 | >100 | 99.4 |
| HOP-62 | 1.61 | 2.51 | 6.78 | 7.48 | >100 | 37 | |
| HOP-92 | 0.14 | 0.219 | 0.48 | 0.655 | >100 | 53.7 | |
| NCI-H226 | 1.07 | 1.73 | 11.2 | 12 | >100 | >100 | |
| NCI-H23 | 0.29 | 0.395 | 0.88 | 2.54 | >100 | 94.2 | |
| NCI-H322M | 0.68 | 1.3 | 6.7 | 6.13 | >100 | >100 | |
| NCI-H460 | 0.45 | 0.569 | 8.78 | 10.7 | >100 | >100 | |
| NCI-H522 | 0.28 | 0.77 | 19.4 | ||||
| Colon Cancer | COLO 205 | 3.23 | 4.48 | 11.2 | 15.6 | 35.8 | 44.4 |
| HCC-2998 | 2.16 | 2.42 | 6.31 | 5.83 | 30.6 | 21.2 | |
| HCT-116 | 0.55 | 1.05 | 3.1 | 2.84 | 93.1 | 7.7 | |
| HCT-15 | 0.48 | 1.22 | 4.05 | 11.4 | 45.9 | >100 | |
| HT29 | 3.63 | 3.43 | 10.6 | 9.93 | 36.5 | 36.6 | |
| KM12 | 0.7 | 1.99 | 10.5 | 10.1 | >100 | 75.5 | |
| SW-620 | 1.28 | 2.1 | 16.5 | 13.7 | >100 | >100 | |
| CNS Cancer | SF-268 | 0.71 | 2.17 | >100 | 24.6 | >100 | >100 |
| SF-539 | 0.53 | 1.78 | 10.8 | 13.7 | 67.8 | 63.8 | |
| SNB-19 | 0.41 | 0.529 | >100 | 15.2 | >100 | >100 | |
| SNB-75 | 1.39 | 9.75 | >100 | ||||
| U251 | 0.42 | 0.633 | 7.23 | 4.97 | 82.9 | 29.7 | |
| Melanoma | LOX IMVI | 0.5 | 0.64 | 3.28 | 3.36 | 26.3 | 21 |
| MALME-3M | 0.4 | 1.02 | 2.26 | 3.48 | >100 | >100 | |
| M14 | 0.68 | 1.38 | 7.16 | 5.37 | >100 | 93.7 | |
| MDA-MB-435 | 0.63 | 1.31 | 6.04 | 4.5 | >100 | 42.7 | |
| SK-MEL-2 | 0.28 | 0.443 | 0.73 | 1.69 | 5.51 | 8.39 | |
| SK-MEL-28 | 0.68 | 0.865 | 7.05 | 9.28 | >100 | >100 | |
| SK-MEL-5 | 0.26 | 0.345 | 0.88 | 1.26 | 4.61 | 4.39 | |
| UACC-257 | 0.29 | 0.815 | 1.59 | 4.84 | >100 | >100 | |
| UACC-62 | 0.28 | 0.319 | 1.14 | 1.22 | 5.59 | 7.21 | |
| Ovarian Cancer | IGROV1 | 0.55 | 0.909 | 24.3 | 10.7 | >100 | >100 |
| OVCAR-3 | 0.44 | 0.674 | 33 | 15.3 | >100 | >100 | |
| OVCAR-4 | 0.86 | 0.841 | >100 | 18.5 | >100 | >100 | |
| OVCAR-5 | 4.04 | 5.55 | >100 | >100 | >100 | >100 | |
| OVCAR-8 | 0.51 | 1.64 | 6.01 | 10.1 | >100 | >100 | |
| NCI/ADR-RES | 0.42 | 0.741 | 10.4 | 9.96 | >100 | >100 | |
| SK-OV-3 | 1.29 | 2.68 | 7.3 | 11.8 | >100 | >100 | |
| Renal cancer | 786-0 | 2.72 | 2.58 | 9.07 | 7.45 | >100 | 39.7 |
| A498 | 0.24 | 0.263 | 1.52 | 1.93 | >100 | >100 | |
| ACHN | 0.82 | 1.73 | 15.5 | 14.4 | >100 | >100 | |
| CAKI-1 | 0.65 | 0.637 | >100 | 4.07 | >100 | >100 | |
| RXF 393 | 1.47 | 2.48 | 5.93 | 6.72 | >100 | 35.2 | |
| SN12C | 0.37 | 0.384 | 12.7 | 4.73 | >100 | >100 | |
| TK-10 | 0.45 | 1.46 | 4.01 | 6.87 | >100 | 82.7 | |
| UO-31 | 0.41 | 1.14 | 7.18 | 6.95 | 37.4 | 32.4 | |
| Prostate Cancer | PC-3 | 0.38 | 1.3 | 3.04 | 5.43 | >100 | 42.8 |
| DU-145 | 1.28 | 2.16 | >100 | 23.4 | >100 | >100 | |
| Breast Cancer | MCF7 | 0.42 | 0.471 | 9.11 | 13.4 | >100 | >100 |
| MDA-MB231/ATCC | 1.06 | 4.76 | 4.08 | 50.5 | >100 | 0 | |
| HS 578T | 0.65 | 1.31 | 28.7 | 8.65 | >100 | >100 | |
| BT-549 | 0.45 | 1.11 | 2.59 | 5.5 | 43.6 | 48.8 | |
| T-47D | 0.29 | 0.449 | 2.74 | 7.49 | >100 | >100 | |
| MDA-MB-468 | 0.3 | 0.425 | 3.17 | 4.42 | >100 | >100 | |
The GI50 = 50% growth inhibition, TGI = total growth inhibition, LC50 = 50% loss of cells.